First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Regeneron (REGN) announced that the FDA has approved Eylea HD Injection 8 mg for the treatment of patients with macular edema following retinal ...

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its chief executive officer, Gregory D. Kunst, will present preclinical data highlighting the ...

The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...

The clinical trial enrolled 38 adults aged 60 and older who had advanced geographic atrophy, the late stage of macular ...

Investing.com -- Regeneron Pharmaceuticals (NASDAQ:REGN) stock rose 3% after the FDA approved its EYLEA HD injection for treating macular edema following retinal vein occlusion (RVO) with up to every ...